(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
As Western heat wave ends, scientists try to make sense of its length and intensity - 2NASA unveils close-up pictures of the comet popping by from another star
- 3Exposure to neighborhood violence leads some Denver teens to use tobacco and alcohol earlier, new study shows
- 4Must-Sit in front of the Programs from Europe and the US
- 52 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
- 6 Shades Brands For Seniors
- NASA releases stunning first images of Earth taken by the Artemis II astronauts
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
- Find the Standards of Viable Refereeing: Settling Debates with Strategy
- The Best 10 Innovation Advancements of the Year
- Venezuelans in Madrid celebrate Maduro's capture
- South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
